Plain-English translation of NCT06203249 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how the microscopic bacteria living in your lungs (your lung microbiome) may affect a rare autoimmune disease called anti-MDA5 antibody positive dermatomyositis, which causes both skin inflammation and progressive lung disease. This study will collect lung fluid samples from patients who have this condition and lung involvement to analyze the relationship between what bacteria live in the lungs and how the disease develops and progresses.
Dermatomyositis with lung complications is a serious condition that is still not fully understood. Scientists believe that the balance of bacteria in the lungs may play a role in how the immune system attacks the body in this disease. By studying this connection, researchers hope to find new ways to predict, prevent, or treat the lung problems that come with this condition.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have already had a bronchoalveolar lavage procedure (a breathing tube inserted to collect fluid from your lungs), which is used for this study. Your lung fluid samples and medical information will be analyzed to look at the types and amounts of bacteria present and how they relate to your disease. The study involves 50 patients total and takes place at a hospital in China.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Sponsor
Chinese PLA General Hospital
Enrollment target
~50 participants
Started
January 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhimei Duan, doctor
Chinese PLA General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.